These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25993174)

  • 21. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
    Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
    Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
    Arnedos M; Scott V; Job B; De La Cruz J; Commo F; Mathieu MC; Wolp-Diniz R; Richon C; Campone M; Bachelot T; Dalenc F; Dessen P; Lacroix L; Lazar V; Soria JC; Delaloge S; Andre F
    Eur J Cancer; 2012 Oct; 48(15):2293-9. PubMed ID: 22840369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapy for breast cancer.
    Mohamed A; Krajewski K; Cakar B; Ma CX
    Am J Pathol; 2013 Oct; 183(4):1096-1112. PubMed ID: 23988612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
    Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
    Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
    Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
    Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
    [No Abstract]   [Full Text] [Related]  

  • 32. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral heterogeneity and subclonal diversification of early breast cancer.
    Yates LR
    Breast; 2017 Aug; 34 Suppl 1():S36-S42. PubMed ID: 28666921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The genomic landscape of breast cancer and its interaction with host immunity.
    Luen S; Virassamy B; Savas P; Salgado R; Loi S
    Breast; 2016 Oct; 29():241-50. PubMed ID: 27481651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.
    Henry NL; Bedard PL; DeMichele A
    Am Soc Clin Oncol Educ Book; 2017; 37():106-115. PubMed ID: 28561710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic Characterization of Primary Invasive Lobular Breast Cancer.
    Desmedt C; Zoppoli G; Gundem G; Pruneri G; Larsimont D; Fornili M; Fumagalli D; Brown D; Rothé F; Vincent D; Kheddoumi N; Rouas G; Majjaj S; Brohée S; Van Loo P; Maisonneuve P; Salgado R; Van Brussel T; Lambrechts D; Bose R; Metzger O; Galant C; Bertucci F; Piccart-Gebhart M; Viale G; Biganzoli E; Campbell PJ; Sotiriou C
    J Clin Oncol; 2016 Jun; 34(16):1872-81. PubMed ID: 26926684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized medicine for metastatic breast cancer.
    Chen TW; Bedard PL
    Curr Opin Oncol; 2013 Nov; 25(6):615-24. PubMed ID: 24097103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
    Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Genomic Landscape of Male Breast Cancers.
    Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS
    Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation matters in precision medicine: A future to believe in.
    Dey N; Williams C; Leyland-Jones B; De P
    Cancer Treat Rev; 2017 Apr; 55():136-149. PubMed ID: 28371665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.